3.96 USD
↗ 0.43 (12.18%)AT CLOSE (11:59 AM EDT)
Briacell Therapeutics Corp. Common Shares
BCTXNASDAQ • USD
3.92
↘ 0.04 (1.14%)
POST MARKET (AS OF 06:24 PM EDT)
Post Market
AS OF 06:24 PM EDT
3.92
↘ 0.04 (1.14%)
Market: OPEN
Shares of Briacell Therapeutics Corp. Common Shares (BCTX) are trading at $3.92. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Aug 19, 2026.
Open?$3.56
High?$4.02
Low?$3.56
Prev. Close?$3.53
Volume?319.1K
Avg. Volume?117.3K
VWAP?$3.81
Rel. Volume?2.72x
Bid / Ask
Bid?$3.01 × 100
Ask?$4.52 × 100
Spread?$1.51
Midpoint?$3.76
Valuation & Ratios
Market Cap?30.7M
Shares Out?8.7M
Float?7.1M
Float %?97.5%
P/E Ratio?N/A
P/B Ratio?1.28
EPS?-$3.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
WEST VANCOUVER, A1 V7T 2X1
Phone: (604) 921-1810
WEST VANCOUVER, A1 V7T 2X1
Phone: (604) 921-1810
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?74
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.85Distress
Confidence?44%Low
Short InterestHigh
Short % of Float?5.78%Elevated
Short Interest?408.3K
Days to Cover?6.0
Free Float7.1M
Avg Daily Volume68.6K
Settlement Date2026-07-31
Financial Health
Current Ratio?7.07Strong
Quick Ratio?7.07Strong
Cash Ratio?1.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.28CHEAP▾
Peers100
S&P92
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-127.5%WEAK▾
S&P3
ROA?-113.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-30951946
Enterprise Value?$23.8M
Fundamentals ratios updated end of day